The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
Source: Alnylam Pharmaceuticals, Inc. For Media Inquiries, please contact: Christine Lindenboom Chief Corporate Communications Officer media@alnylam.com 617-682-4340 For Investor Inquiries, please contact: Josh Brodsky VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276...
Investor Relations:INVESTORS@ALNYLAM.COM Business Development:BUSINESSDEVELOPMENT@ ALNYLAM.COM General:INFO@ALNYLAM.COM Alnylam Assist® (Alnylam Patient Support):833.256.2748 Compliance Helpline:800.231.8685helpline.alnylam.com Alnylam Pharmaceuticals, Inc – Corporate Headquarters 675 West Kendall St Camb...
Alnylam submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisir. Investor Relations | Alnylam Pharmaceuticals, Inc. October 9, 2024. Accessed October 11, 2024. https://investors.alnylam.com/press-release?id=28446. Galant NJ, Westermark P, Higaki...
Alnylam Pharmaceuticals.The article reports on the disclosure of results for neurological drug patisiran of Alnylam Pharmaceuticals Inc., a biopharmaceutical company based in Cambridge, Massachusetts and discusses the financial performance of the company in the first quarter of 2015.Investor's...
AboutAlnylam Pharmaceuticals Alnylam(Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winn...
Prior to joining Amgen, she worked at FleishmanHillard, a public relations firm, supporting various pharmaceutical and biotech clients, and she started her career in the communications group of Millennium Pharmaceuticals, where she helped launch VELCADE. Christine is a member of the Board of ...
Regeneron Pharmaceuticals (Nasdaq: REGN ) and Alnylam Pharmaceuticals, Inc. announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment o
, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company's lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), an...
The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.